

Joël Jean-Mairet succeeded in selling his company for good money. Now he offers valuable tips about the things young ETH entrepreneurs should look out for.

[more>](#)

Jan 2014

20 Minuten online

Pro Jahr erleiden in der Schweiz etwa 10 000 Menschen eine Medikamentenvergiftung. Ein universelles Gegenmittel entwickelt derzeit **Versantis**, eine Spin-off-Firma der ETH

Zürich.

[more>](#)



Dr. Vincent Forster konnte sich mit seiner neuen Spin-off **Versantis** unter die TOP 10 der Preisträger des diesjährigen McKinsey & ETHZ "Venture" Wettbewerbs qualifizieren.

[more>](#)

Nov 2013



NZZ Arikel: **Brot ohne Schmerzen geniessen**

Grundnahrungsmittel wie Brot und Teigwaren enthalten Gluten, das rund ein Prozent der Bevölkerung nicht verträgt. Prof. Leroux an der ETH forscht an Therapien, die diesen Menschen das Leben erleichtern würden. [more >](#)

October 2013



We congratulate Maurizio Roveri for winning the **Poster Award** at the **Children's Research Center (CRC) Retreat** in Au on the 31st of October

2013.

Titel of the poster:

Improving treatment of pediatric sarcomas through targeted liposomal drug delivery

Verleihung der **Rottendorf-Wissenschaftspreise 2013** an Dr. Gregor Fuhrmann, ETH Zürich

Dr. Gregor Fuhrmann erhält den Europa-Preis der Stiftung für seine Untersuchungen zum Thema Zöliakie und Enzyme - Neue Ansätze gegen Weizenallergie. [more >](#)


May 2013

Polymere schützen Enzyme

ETH-Forscher der Gruppe Leroux haben eine Methode entwickelt, mit der die Enzyme bei ihrer Reise durch den Magen-Darm-Trakt viel länger aktiv bleiben. Damit könnten in Zukunft möglicherweise Nahrungsmittelunverträglichkeiten behandelt werden. [more >](#)

«Ohne den Schutz der Polymere werden die Enzyme im Magen innert Minuten inaktiv. Die von den Polymeren abgeschirmten Enzyme arbeiteten dagegen bis zu drei Stunden lang weiter», sagt Prof. Jean-Christophe Leroux, Leiter der Forschungsarbeit.


Congratulation to [Vincent Forster](#) who got admitted to the [ETH Pioneer Fellowship program](#). He will join the [Innovation and Entrepreneurship Lab](#) to transfer an innovative therapy for rare metabolic diseases a step closer to a clinical implementation. Cheers and good luck for this new adventure!



Universal antidote: **A.** an ill patient with high toxin blood concentration (hence the green blood vessels) begins a peritoneal dialysis therapy. During the dialysis (**B**), the toxin diffuses from the blood vessels (BV) through the peritoneal membrane (PM) and gets trapped in the liposomes (L). This process progressively reduces the toxin blood and organ concentrations below toxic levels. Finally (**C**), all toxic molecules have successfully been extracted from the organisms and concentrated in the dialysate which is withdrawn extracorporeally.

April 2013

[Mattias Ivarsson](#) and [Bastien Castagner](#) have had a video produced that explains the mechanism of action of *Clostridium difficile* toxins.



21.03.2013 - Spark Award der ETH

Our group has been selected among the top 20 most promising inventions of the year



Photo: Oliver Bartenschlager / ETH Zurich

01.12.2012

Dr. Madduri Srinivas was awarded with first prize in basic science at ESPU-2012 congress. His work has been further recognized for winning C. E. Alken prize for the best research in Uro-neurological tissue regeneration.

01.12.2012

Congratulations to Mattias Ivarsson for winning a prize for his oral presentation at the GPEN meeting in Melbourne, Australia.

ETH Tag 2012


Prof. Dr. Jean-Christophe Leroux got awarded with the "Goldene Eule" of VSETH - congratulations!



2012 Award Goldene Eule

29.08.2012

We congratulate Mi Liu for his prize winning poster presentation.




Poster Award - 1st price at the **Swiss Pharma Day 2012** in Bern.

Titel of the poster:

Comb-polymer monolayers displaying molecular sieving properties for the smart PEGylation of proteins

23.07.12

Toxine statt Bakterien bekämpfen



ETH Wissenschaftler der Forschungsgruppe Drug Formulation and Delivery

von Jean-Christophe Leroux am Institut für Pharmazeutische Wissenschaften haben einen neuen Wirkstoff gegen ein krankmachendes Darmbakterium entwickelt. Anders als herkömmliche Therapien zielt ihre Behandlung nicht auf das Bakterium selbst, sondern auf das Gift, das dieses absondert. Der grosse Vorteil: Der neue Ansatz kommt ohne Antibiotika aus. Das Patent ist eingereicht.

more>

May 2012



Sola Stafette ([see more>](#))

April 2012

Mattias Ivarsson and **Bastien Castagner** have been granted CHF 10'000 by Venture Kick for their business idea for the development of new treatments for *Clostridium difficile* infection.



March 2012

Qualified for the **Spark Award 2012**

Neue Substanz zur Bekämpfung einer typischen Spitalinfektion, ausgelöst durch das Darm-Bakterium «Clostridium difficile». Die entwickelte Substanz verhindert das Eindringen des Gifts in die Dickdarm-Zellen, indem sie das Toxin bereits vorher unschädlich macht (Gruppe von Professor Jean-Christophe Leroux). [more>](#)



Finalists of the Spark Award 2012

February 2012

Congratulations!

„The G-rockets“ (formerly known as the Galenik Raketen) came in 3rd place at this year's PSA Unihockey tournament held at the Sports Centre in Höggerberg on the 5th of February.



„The G-rockets“

January 2012

Vincent Forster has won the Best Poster Award

anlässlich des **Swiss Experimental Surgery Symposium 2012** der University of Geneva

November 2011

Die wichtigsten Entwicklungen in der Galenik laufen im Bereich der Nanomedizin, sagt ETH-Forscher Jean-Christophe Leroux.

Bereits hat die Forschungsgruppe des Kanadiers ein solches Polymer entwickelt (und patentiert), welches Gluten bindet und aus dem Verkehr zieht. Gluten ist ein Getreideeiweiss, das bei Menschen mit entsprechender Veranlagung Zöliakie auslösen kann, eine chronische Entzündung der Darmschleimhaut.

[Sonntagszeitung 27. Nov. 2011](#)

August 2011

Glowing abdomens reveal enzyme activity

Professor Jean-Christophe Leroux and his colleagues have developed a method with which they can observe gluten-splitting enzymes in a living organism. This is an important step towards developing effective digestive proteins that can be used against coeliac disease. ([ETH life](#))

[2011 Tsuneji Nagai Postdoctoral Fellowship Winner](#)

Soo Hyeon Lee of the Korea Advanced Institute of Science and Technology was chosen as the 2011 Tsuneji Nagai Postdoctoral Fellowship Winner, and will be receiving the \$30,000 award from the award's namesake, Tsuneji Nagai, during the 38th CRS Annual Meeting & Exposition.

June 2011

The polymeric binder which was **developed by Prof. Leroux** while he was at the University of Montreal has been licensed to Biolinex. It will be further evaluated as potential supportive therapy for celiac disease.

[more>](#)



Congratulations to the winners of the GPEN 2010 outstanding podium awards!

1st: Deborah Goldberg, University of Maryland

2nd: Emmy Dolman, Utrecht University

3rd: Elisabeth Giger, ETH-Zurich

Congratulations to all the winners and thank you to all the students and post-doctoral fellows that presented their work at GPEN 2010.

Sincerely,

GPEN 2010 Organizing Committee


We are proud to announce that

Lorine Brülisauer has been awarded a **SSCI scholarship** for her PhD studies.

Congratulation!

Poster Award - 2nd price

We congratulate Kathrin Fuhrmann for her prize winning poster presentation during the **Swiss Pharma Day 2010** in Bern.



An interview of Prof Leroux

with Radio Suisse Romande on Celiac Disease



September 2, 2010 - Lausanne, Switzerland

Professor Leroux from ETH receives the [Debiopharm Life Sciences Award 2010](#)

- One of the most creative researchers of his generation in pharmaceutical technology -



Drug Formulation & Delivery